Jason R Stubbs1,2, Margaret R Stedman3, Sai Liu3, Jin Long3, Yoko Franchetti4, Raymond E West4, Alexander J Prokopienko4, Jonathan D Mahnken5,6, Glenn M Chertow3, Thomas D Nolin4. 1. The Jared Grantham Kidney Institute, jstubbs@kumc.edu. 2. Division of Nephrology and Hypertension, and. 3. Division of Nephrology, Stanford University School of Medicine, Palo Alto, California; and. 4. Department of Pharmacy and Therapeutics, Center for Clinical Pharmaceutical, Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania. 5. The Jared Grantham Kidney Institute. 6. Department of Biostatistics, University of Kansas Medical Center, Kansas City, Kansas.
Abstract
BACKGROUND AND OBJECTIVES: Trimethylamine N-oxide (TMAO), a compound derived from byproducts of intestinal bacteria, has been shown to accelerate atherosclerosis in rodents. To date, there are conflicting data regarding the association of serum TMAO with cardiovascular outcomes in patients with ESKD, a population exhibiting both high serum TMAO and excessive atherosclerosis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We measured baseline serum TMAO concentrations in a subset of participants (n=1243) from the Evaluation of Cinacalcet Hydrochloride Therapy to Lower Cardiovascular Events (EVOLVE) trial and conducted post hoc analyses evaluating the association between baseline serum TMAO and cardiovascular outcomes. RESULTS: We observed a wide distribution of serum TMAO in our cohort, with approximately 80% of participants exhibiting TMAO concentrations ≥56 µM and a maximum TMAO concentration of 1103.1 µM. We found no association between TMAO and our primary outcome, a composite of cardiovascular mortality, myocardial infarction, peripheral vascular event, stroke, and hospitalization for unstable angina. Moreover, in unadjusted and adjusted analyses, we observed no relation between TMAO and all-cause mortality, the independent components of our composite outcome, or the original EVOLVE primary outcome. Although we did observe higher TMAO concentrations in white participants, further subgroup analyses did not confirm the previously identified interaction between TMAO and race observed in a prior study in patients receiving dialysis. CONCLUSIONS: We found no evidence linking TMAO to adverse clinical outcomes in patients receiving maintenance hemodialysis with moderate to severe secondary hyperparathyroidism.
BACKGROUND AND OBJECTIVES:Trimethylamine N-oxide (TMAO), a compound derived from byproducts of intestinal bacteria, has been shown to accelerate atherosclerosis in rodents. To date, there are conflicting data regarding the association of serum TMAO with cardiovascular outcomes in patients with ESKD, a population exhibiting both high serum TMAO and excessive atherosclerosis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We measured baseline serum TMAO concentrations in a subset of participants (n=1243) from the Evaluation of Cinacalcet Hydrochloride Therapy to Lower Cardiovascular Events (EVOLVE) trial and conducted post hoc analyses evaluating the association between baseline serum TMAO and cardiovascular outcomes. RESULTS: We observed a wide distribution of serum TMAO in our cohort, with approximately 80% of participants exhibiting TMAO concentrations ≥56 µM and a maximum TMAO concentration of 1103.1 µM. We found no association between TMAO and our primary outcome, a composite of cardiovascular mortality, myocardial infarction, peripheral vascular event, stroke, and hospitalization for unstable angina. Moreover, in unadjusted and adjusted analyses, we observed no relation between TMAO and all-cause mortality, the independent components of our composite outcome, or the original EVOLVE primary outcome. Although we did observe higher TMAO concentrations in white participants, further subgroup analyses did not confirm the previously identified interaction between TMAO and race observed in a prior study in patients receiving dialysis. CONCLUSIONS: We found no evidence linking TMAO to adverse clinical outcomes in patients receiving maintenance hemodialysis with moderate to severe secondary hyperparathyroidism.
Authors: Christopher W McIntyre; Laura E A Harrison; M Tarek Eldehni; Helen J Jefferies; Cheuk-Chun Szeto; Stephen G John; Mhairi K Sigrist; James O Burton; Daljit Hothi; Shvan Korsheed; Paul J Owen; Ka-Bik Lai; Philip K T Li Journal: Clin J Am Soc Nephrol Date: 2010-09-28 Impact factor: 8.237
Authors: Eugene P Rhee; Amanda Souza; Laurie Farrell; Martin R Pollak; Gregory D Lewis; David J R Steele; Ravi Thadhani; Clary B Clish; Anna Greka; Robert E Gerszten Journal: J Am Soc Nephrol Date: 2010-04-08 Impact factor: 10.121
Authors: P Jungers; Z A Massy; T Nguyen Khoa; C Fumeron; M Labrunie; B Lacour; B Descamps-Latscha; N K Man Journal: Nephrol Dial Transplant Date: 1997-12 Impact factor: 5.992
Authors: Sylwia Olechnowicz-Tietz; Anna Gluba; Anna Paradowska; Maciej Banach; Jacek Rysz Journal: Int Urol Nephrol Date: 2013-03-13 Impact factor: 2.370
Authors: Carlee I Oakley; Julian A Vallejo; Derek Wang; Mark A Gray; LeAnn M Tiede-Lewis; Tilitha Shawgo; Emmanuel Daon; George Zorn; Jason R Stubbs; Michael J Wacker Journal: Am J Physiol Heart Circ Physiol Date: 2020-04-03 Impact factor: 4.733
Authors: Nilaksh Gupta; Jennifer A Buffa; Adam B Roberts; Naseer Sangwan; Sarah M Skye; Lin Li; Karen J Ho; John Varga; Joseph A DiDonato; W H Wilson Tang; Stanley L Hazen Journal: Arterioscler Thromb Vasc Biol Date: 2020-03-26 Impact factor: 8.311
Authors: Gretchen N Wiese; Annabel Biruete; Ranjani N Moorthi; Sharon M Moe; Stephen R Lindemann; Kathleen M Hill Gallant Journal: J Ren Nutr Date: 2020-06-29 Impact factor: 3.655